As announced on November 13, 2024, the Company's Board of Directors authorized a new share repurchase program to repurchase up to $300 million of the Company's common stock (the "New Program"). On December 2, 2024, the Company entered into a new written trading plan under Rule 10b5-1 of the Exchange Act, to facilitate repurchases under the New Program. The plan permits the purchase of up to approximately $300 million of the Company’s common stock from December 2, 2024 through December 2, 2029.

The New Program may be suspended or discontinued at any time and is funded using the Company’s available cash, cash equivalents and short-term investments. Under the New Program, shares may be repurchased through open market and/or privately negotiated transactions at prices deemed appropriate by management. The timing and amount of repurchase transactions under the New Program depend on market conditions as well as corporate and regulatory considerations.

During the three and six months ended April 4, 2026, the Company repurchased a total of approximately 3.0 thousand and 171.0 thousand shares of common stock under the New Program at a cost of approximately $0.1 million and $6.8 million, respectively.

The stock repurchases were recorded in the periods the repurchased shares were delivered and accounted for as treasury stock in the Company’s Consolidated Condensed Balance Sheets. The Company records treasury stock purchases under the cost method using the first-in, first-out (FIFO) method. Upon re-issuance of treasury stock, amounts in excess of the acquisition cost are credited to additional paid-in capital.

If the Company reissues treasury stock at an amount below its acquisition cost and additional paid-in capital associated with prior treasury stock transactions is insufficient to cover the difference between acquisition cost and the reissue price, this difference is recorded against retained earnings.


(in thousands)	Cumulative Foreign Currency Translation Adjustment		Pension Plan Adjustments		(Loss) / Gain on Derivative Instruments		Total





As of October 4, 2025	$	(22,169)	$	(1,766)	$	85	$	(23,850)
Other comprehensive income / (loss) before reclassifications	1,111		11		(552)		570
Amount reclassified out of accumulated other comprehensive income / (loss)	—		—		(4)		(4)
Tax effects	(176)		—		—		(176)
Accumulated other comprehensive income / (loss)	935		11		(556)		390
As of April 4, 2026	$	(21,234)	$	(1,755)	$	(471)	$	(23,460)

The Company has a stockholder-approved equity-based compensation plan, the 2021 Omnibus Incentive Plan (the “Plan”) from which employees and directors receive grants. As of April 4, 2026, 3.4 million shares of common stock are available for grant to the Company’s employees and directors under the Plan.

•Relative Total Shareholder Return Performance Share Units (“Relative TSR PSUs”) entitle the employee to receive common stock of the Company on the award vesting date, typically the third anniversary of the grant date (or as soon as administratively practicable if later), if market performance objectives which measure the relative TSR are attained. Relative TSR is calculated based upon the 90-calendar day average price at the end of the performance period of the Company’s stock as compared to specific peer companies that comprise the GICS (45301020) Semiconductor Index. TSR is measured for the Company and each peer company over a performance period, which is generally three years. Vesting percentages range from 0% to 200% of awards granted. The provisions of the Relative TSR PSUs are reflected in the grant date fair value of the award; therefore, compensation expense is recognized regardless of whether the market condition is ultimately satisfied. Compensation expense is reversed if the award is forfeited prior to the vesting date.

•Revenue Growth Performance Share Units (“Growth PSUs”) entitle the employee to receive common stock of the Company on the award vesting date, typically the third anniversary of the grant date (or as soon as administratively practicable if later), based on organic revenue growth objectives and relative growth performance against named competitors as set by the Management Development and Compensation Committee (“MDCC”) of the Company’s Board of Directors. Organic revenue growth is calculated by averaging revenue growth (net of revenues from acquisitions) over a performance period, which is generally three years. Revenues from acquisitions will be included in the calculation after four fiscal quarters after acquisition. Any portion of the grant that does not meet the revenue growth objectives and relative growth performance is forfeited. Vesting percentages range from 0% to 200% of awards granted.

•In general, Time-based Restricted Share Units (“Time-based RSUs”) awarded to employees vest ratably over a three-year period on the anniversary of the grant date provided the employee remains employed by the Company.

Equity-based compensation expense recognized in the Consolidated Condensed Statements of Operations for the three and six months ended April 4, 2026 and March 29, 2025 was based upon awards ultimately expected to vest, with forfeiture accounted for when they occur.


	Three months ended		Six months ended
(shares in thousands)	April 4, 2026	March 29, 2025	April 4, 2026	March 29, 2025
Time-based RSUs	—	—	568	563
Relative TSR PSUs	—	—	75	128

Common stock	5	7	11	14
Equity-based compensation in shares	5	7	654	705

The following table reflects total equity-based compensation expense, which includes Time-based RSUs, Relative TSR PSUs, Growth PSUs and common stock, included in the Consolidated Condensed Statements of Operations during the three and six months ended April 4, 2026 and March 29, 2025:





	Three months ended				Six months ended
(in thousands)	April 4, 2026		March 29, 2025		April 4, 2026		March 29, 2025
Cost of sales	$	427	$	387	$	864	$	770
Selling, general and administrative	4,398		4,920		7,290		8,659
Research and development	2,166		2,186		4,167		4,205
Total equity-based compensation expense	$	6,991	$	7,493	$	12,321	$	13,634





	Three months ended				Six months ended
(in thousands)	April 4, 2026		March 29, 2025		April 4, 2026		March 29, 2025
Time-based RSUs	$	5,094	$	5,210	$	10,107	$	10,366
Relative TSR PSUs	1,628		1,837		3,087		3,615
Growth PSUs	—		131		(1,412)		(977)

Common stock	269		315		539		630
Total equity-based compensation expense	$	6,991	$	7,493	$	12,321	$	13,634